Iopidine (Apraclonidine)

Apraclonidine acts as a selective alpha‑2 adrenergic receptor agonist in the eye. Stimulation of these receptors reduces the production of aqueous humor and modestly increases uveoscleral outflow, together leading to a decrease in intraocular pressure.

The dosing regimen for Iopidine is determined by the prescribing clinician based on the individual’s condition and response. Typically, one drop is instilled in the affected eye(s) as directed, but the exact frequency and duration are set by the healthcare professional.

Safety data for apraclonidine in pregnancy and lactation are limited. It should be used only if the potential benefit outweighs any possible risk to the fetus or infant, and the decision should be made in consultation with a qualified healthcare provider.

To request Iopidine, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Iopidine belongs to the alpha‑2 adrenergic agonist class, offering a modest IOP‑lowering effect with a different mechanism than beta‑blockers like timolol or prostaglandin analogues. It is often used as an adjunct or alternative when patients cannot tolerate other classes, providing an additional therapeutic option.

Store Iopidine eye drops at room temperature, below 25 °C, in the original packaging. Keep the bottle tightly closed, protect it from light and moisture, and discard any product that appears discolored or contaminated.

Iopidine is applied as an ophthalmic solution. The patient should wash hands, tilt the head back, pull down the lower eyelid, and place a single drop into the conjunctival sac. Close the eye gently and avoid blinking or rubbing for a few minutes to allow absorption.

Serious adverse events, though rare, include severe allergic reactions such as angio‑edema, significant systemic hypotension, persistent ocular inflammation, corneal edema, and sudden loss of vision. Any of these symptoms require immediate medical attention.

Iopidine is contraindicated in patients with known hypersensitivity to apraclonidine or any component of the formulation. Caution is also advised for individuals with severe cardiovascular disease, uncontrolled systemic hypotension, or those using other potent ocular hypotensive agents without close monitoring.